-
1
A nationwide cohort study in Sweden compared infection-related hospitalizations between rituximab and ocrelizumab in multiple sclerosis patients.
-
2
The study included 9,704 rituximab, 148 ocrelizumab, and 7,020 other DMT treatment starts, with an average follow-up of 5.4 years for rituximab.
-
3
The crude rate of serious infections was 22 per 1,000 person-years on rituximab and 30 on ocrelizumab, both significantly higher than other DMTs.
-
4
Antibiotic use was approximately 10 times more frequent than serious infections, with adjusted rates increased by 26% for rituximab and 73% for ocrelizumab.
-
5
The relapse rate was significantly lower for ocrelizumab compared to rituximab, indicating differences in treatment efficacy.
